

#startupoftheday 144- Amaterasu Life Sciences

12 April 2022 | Features

Endeavouring to build value by developing personnel care, health and wellness

Inception- 2016

Location- Mumbai

Domain- Pharma manufacturing/ Healthcare

Founders- Rustomjee Maharukh and Rustomjee Mahafirin

Total team strength- 23

Total funds raised- Self-funded

Investors- NA

Revenue generated since inception- NA

Key highlights-

- 3 patents, 6 innovative commercialized products, 10 products in pipeline, over Rs 6.5 crore in R&D investment by its promoter
- Developed unique and patented protective layer technology in skin care segment and designed two unique products to prevent chafing and bedsores
- Working toward building two new categories with launch of Skineasi and Soreze range of products
- Developed and established proof of concept for single dose anti-malaria injection that will revolutionize the way malaria is treated in India and world over

- Filed patent and hopes huge commercial success upon the launch of single dose anti-malaria injection
- Partnered with US based company for developing and filing of innovative range of depot injection in neuro-psychiatry segment. This will be another first of its kind technology that is already protected by patent filing
- To create new category in anti-chafing, bedsores and adult diaper rash segment
- To take its long-acting injections portfolio to the IND (US and other global regulated markets) filing stage and out license to marketing partner for future revenues and profits
- Seeking govt. funds for furthering anti-malaria project, and is also critical for its future growth

Founder Speaks-

"Excellent growth opportunities for Amaterasu considering the niche segment it occupies in market. More importantly Amaterasu is backed by innovative R&D and healthy product pipeline which forms the back bone of Amaterasu. Though growth could be slow initially as we are trying to build new categories. Amaterasu plans to expand its marketing operations from digital first to offline marketing for its skin protection range.

The long-acting injection portfolio are high-value developments targeted for global and regulated markets. Amaterasu plans to find an appropriate marketing partner/s who would be able to commercialize these unique products across the world. While the growth potential for these products is immense but the gestational horizon is about 3 to 5 years along with high investments in R&D."

- Maharukh Rustomjee, Chief Scientist & Managing Partner, Amaterasu Life Sciences LLP, Mumbai